Get the Stockscreener App
1.32
1.49%
-0.02
After Hours:
1.29
-0.03
-2.27%
Avenue Therapeutics Inc stock is traded at $1.32, with a volume of 176.67K.
It is down -1.49% in the last 24 hours and down -31.96% over the past month.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
See More
Previous Close:
$1.34
Open:
$1.3
24h Volume:
176.67K
Relative Volume:
0.49
Market Cap:
$2.71M
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.3465
EPS:
-3.81
Net Cash Flow:
$-12.45M
1W Performance:
-28.26%
1M Performance:
-31.96%
6M Performance:
-52.69%
1Y Performance:
-88.27%
1-Day Range:
$1.26
$1.36
1-Week Range:
$1.26
$2.06
52-Week Range:
$1.26
$15.00
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare ATXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
1.32 | 2.71M | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Trajan Group Director Increases Stake Through Options - MSN
Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN
How Are Things Looking For Zeta Global Holdings Corp (NYSE: ZETA) For The Short Term? - Stocks Register
Avenue Therapeutics stock hits 52-week low at $1.5 amid challenges - Investing.com
Park Avenue Securities LLC Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
13,028 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Park Avenue Securities LLC - Defense World
Park Avenue Securities LLC Buys Shares of 1,684 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Assenagon Asset Management S.A. Sells 65,316 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Wall Street-Heavily Traded - WDRB
PLRX (Pliant Therapeutics) Momentum Rank : 7 (As of Jan. 24, 2025) - GuruFocus.com
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Assenagon Asset Management S.A. - Defense World
Healthcare Triangle Faces Potential Delisting, Plans Annual Meeting - MSN
Assenagon Asset Management S.A. Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Park Avenue Securities LLC - Defense World
Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Hennion & Walsh Asset Management Inc. Takes Position in Autolus Therapeutics plc (NASDAQ:AUTL) - Defense World
Assenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
AVTX (Avalo Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
JPMorgan Chase & Co. Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - Defense World
Coeptis Therapeutics (Nasdaq: COEP) Emerges as a Biopharma Innovator Leveraging AI-Driven Marketing - Barchart
Jane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Avadel Pharmaceuticals (NASDAQ:AVDL) Hits New 1-Year Low After Analyst Downgrade - Defense World
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month Low After Analyst Downgrade - Defense World
Comparing Galectin Therapeutics (NASDAQ:GALT) and Avenue Therapeutics (NASDAQ:ATXI) - Defense World
Analyzing Finch Therapeutics Group (NASDAQ:FNCH) and Alvotech (NASDAQ:ALVO) - Defense World
Head to Head Analysis: Immunome (NASDAQ:IMNM) vs. Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Context Therapeutics (NASDAQ:CNTX) Raised to Strong-Buy at Citizens Jmp - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World
Jane Street Group LLC Lowers Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
State Street Corp Sells 47,600 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) - Defense World
Jane Street Group LLC Has $681,000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
State Street Corp Grows Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
State Street Corp Purchases 16,188 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Jane Street Group LLC Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Drug Resistant Epilepsy Market Growth, Trends & Key Players - openPR
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by XTX Topco Ltd - Defense World
Subaru Corp Leads Third Avenue Value Fund's Strategic Moves in Q4 2024 - Yahoo Finance
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts By Investing.com - Investing.com South Africa
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts - Investing.com Australia
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Postoperative Pain Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight - The Globe and Mail
SEC Form S-1 filed by Qualigen Therapeutics Inc. - Quantisnow
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
Janux Therapeutics Announces Proposed Public Offering - Business Wire
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):